A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OZANIMOD, AN ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF THE MAINTENANCE PERIOD OF THE TOUCHSTONE STUDY

William Sandborn  1    
1 University of California San Diego

Pathway
Chairman's Choice, Digestive Oncology, Disease Mechanisms, Endoscopy, Gut Microbiota, Hepatobiliary, Histopathology, IBD, Immunology, Neurogastroenterology & Motility, Oesophagus, Paediatrics, Pancreas, Primary Care, Radiology & Imaging, Small Intestine & Nutrition, Stomach & H. Pylori, Surgery, Young GI Track

Conference
UEG Week 2015


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing